## WHAT IS CLAIMED IS:

- 1. An isolated nucleic acid which comprises a nucleotide sequence of a polymorphic region of a CADPKL allelic variant, wherein the CADPKL allelic variant has a nucleotide sequence that differs from a reference nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4 and complementary sequences thereof.
- 2. The isolated nucleic acid of claim 1 wherein the polymorphic region is located in a 5' promoter region.
- 3. The isolated nucleic acid of claim 1 wherein the polymorphic region is located in an intron.
- 4. The isolated nucleic acid of claim 1 wherein the polymorphic region is located in an exon.
- 5. The isolated nucleic acid of claim 1 which comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:37-42, SEQ ID NOS:77-90, and complementary sequences thereof.
- 6. A kit for amplifying or determining the molecular structure of at least a portion of a CADPKL nucleic acid, which kit comprises:
  - a probe or primer capable of hybridizing to a polymorphic region of a CADPKL nucleic acid; and instructions for use.

- 7. The kit of claim 6, wherein the CADPKL nucleic acid is from a human CADPKL gene.
- 8. The kit of claim 7 wherein the probe or primer is capable of hybridizing to a polymorphic region of a CADPKL allelic variant, which CADPKL allelic variant has a nucleotide sequence that differs from a reference nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4 and complementary sequences thereof.
- 9. The kit of claim 8 wherein the polymorphic region is located in a 5' promoter region.
- 10. The kit of claim 8 wherein the polymorphic region is located in a 3' untranslated region.
  - 11. The kit of claim 8 wherein the polymorphic region is located in an intron.
  - 12. The kit of claim 8 wherein the polymoprhic region is located in an exon.
- 13. The kit of claim 8 wherein the polymorphic region comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:37-42, SEQ ID NOS;77-90, and complementary sequences thereof.
- 14. The kit of claim 8 wherein the probe or primer is a single stranded nucleic acid.
  - 15. The kit of claim 8 wherein the probe or primer is labeled.

- 16. The kit of claim 8 wherein the probe or primer has a nucleotide sequence from about 15 to about 30 nucleotides in length.
- 17. The kit of claim 16 wherein the probe or primer comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:8-35, SEQ ID NOS:37-42, SEQ ID NOS:51-90, and complementary sequences thereof.
- 18. A kit according to claim 16 which comprises a first primer and a second primer, wherein the first and second primers are selected from the group consisting of SEQ ID NOS:8-35, SEQ ID NOS:37-42, SEQ ID NOS: 51-90, and complementary sequences thereof.
- 19. A kit for determining whether a subject is at risk of developing a neuropsychiatric disorder, which kit comprises:

a probe or primer that is capable of hybridizing to a polymorphic region of a CADPKL nucleic acid; and

instructions for use.

- 20. The kit of claim 19, wherein the neuropsychiatric disorder is schizophrenia, schizoaffective disorder, bipolar disorder, unipolar affective disorder and adolescent conduct disorder.
- 21. A method for detecting a CADPKL allelic variant, which method comprises contacting a sample CADPKL nucleic acid with a probe or primer complementary to a polymorphic region of a CADPKL allelic variant so that the CADPKL allelic variant is detected in the sample CADPKL nucleic acid.

- 22. The method of claim 21 wherein the nucleotide sequence of the CADPKL allelic variant differs from a reference nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:4.
- 23. The method of claim 21 further comprising determining the identity of the CADPKL allelic variant.
- 24. A method according to claim 23 which comprises determining the identity of at least one nucleotide of the sample CADPKL nucleic acid.
- 25. The method of claim 24 wherein the sequence of the polymorphic region of the sample CADPKL nucleic acid is determined.
- 26. The method of claim 23 wherein the identity of the CADPKL allelic variant is determined by restriction enzyme analysis.
- 27. The method of claim 23 wherein the identity of the CADPKL allelic variant is determined by single-stranded conformational polymorphism.
- 28. The method of claim 23 wherein the identity of the CADPKL allelic variant is determined by allelic specific hybridization.
- 29. The method of claim 21 wherein the identity of the CADPKL allelic variant is determined by primer specific extension.
- 30. The method of claim 21 wherein the identity of the CADPKL allelic variant is determined by an oligonucleotide ligation assay.

- 31. The method of claim 21 wherein the CADPKL allelic variant is an allelic variant of a human CADPKL gene.
- 32. The method of claim 21 wherein the nucleotide sequence of the probe or primer is from about 15 to about 30 nucleotides in length.
- 33. The method of claim 32 wherein the probe or primer comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:8-35, SEQ ID NOS:37-42, SEQ ID NOS:51-90, and complementary sequences thereof.
- 34. A method according to claim 21 which further comprises contacting the sample CADPKL nucleic acid with a second probe or primer, wherein each probe or primer has a nucleotide sequence selected from the group consisting of SEQ ID NOS:8-35, SEQ ID NOS:37-42, SEQ ID NOS:51-90, and complementary sequences thereof.
- 35. The method of claim 34 which comprises hybridizing the two probes or primers to the sample CADPKL nucleic acid.
- 36. The method of claim 21 wherein the probe or primer is a single stranded nucleic acid.
  - 37. The method of claim 21 wherein the probe or primer is labeled.
- 38. A method for determining whether a subject has or is at risk of developing a disease or disorder associated with a specific CADPKL allelic variant, which method comprises identifying, according to the method of claim 21, the CADPKL allelic variant in a nucleic acid sample from the subject.

- 39. The method of claim 38 wherein the disease or disorder is a neuropsychiatric disorder.
- 40. The method of claim 39 wherein the neuropsychiatric disorder is selected from the group consisting of schizophrenia, schizoaffective disorder, bipolar disorder, unipolar affective disorder and adolescent conduct disorder.
- 41. The method of claim 40 wherein the neuropsychiatric disorder is schizophrenia.
- 42. A method for selecting an appropriate drug for administration to an individual, which method comprises determining the molecular structure of at least a portion of the CADPKL gene of the individual.
- 43. The method of claim 42 wherein the molecular structure is determined according to a method that comprises determining the identity of an allelic variant of at least one polymorphic region of the CADPKL gene of the individual.
- 44. A method for treating a subject having a disease or disorder associated with a specific allelic variant of a polymorphic region of a CADPKL gene, which method comprises:
  - (a) determining the identity of the allelic variant; and
  - (b) administering, to the subject, a compound that compensates for the effect of the specific allelic variant.
- 45. The method of claim 44 wherein the compound is a CADPKL protein activity inhibitor.
  - 46. The method of claim 44 wherein the polymorphic region is located in an exon.

- 47. The method of claim 44 wherein the polymorphic region is located in an intron.
  - 48. The method of claim 44 wherein the specific allelic variant is a mutant allele.
- 49. The method of claim 44 wherein the polymorphic region is located in a promoter region.
- 50. The method of claim 44 wherein the sequence of the specific allelic variant comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:8-35, SEQ ID NOS:37-42, SEQ ID NOS:51-90, and complementary sequences thereof.
- 51. The method of claim 44 wherein the specific allelic variant is associated with a neuropsychiatric disorder.
- 52. The method of claim 51 wherein the neuropsychiatric disorder is selected from the group consisting of schizophrenia, schizoaffective disorder, bipolar disorder, unipolar affective disorder and adolescent conduct disorder.
- 53. The method of claim 44 wherein the compound modulates CADPKL protein activity levels.
- 54. An isolated CADPKL nucleic acid which comprises a microsatellite repeat, and which is amplifiable from a genomic DNA using PCR and any primer pair disclosed in Table 4A.

- 55. The isolated CADPKL nucleic acid of claim 54, wherein the microsatellite repeat comprises a motif selected from the group consisting of CA, CT, GT, AG, ATTGG, and all complements and permutations of said motif.
- 56. The isolated CADPKL nucleic acid of claim 54, wherein the microsatellite repeat comprises a repeat motif selected from the group consisting of  $(GT)_n$ ,  $(GT)_{nl}$   $(AG)_{n2}$ ,  $(CT)_n$ ,  $(CA)_n$ ,  $(ATTGG)_n$ , and all complements of said repeat motif.
- 57. A method for detecting a CADPKL allelic variant, which method comprises contacting a sample CADPKL nucleic acid with a probe or primer complementary to a microsatellite repeat of a CADPKL allelic variant so that the CADPKL allelic variant is detected in the sample CADPKL nucleic acid.
- 58. A method for determining whether a subject has or is at risk of developing a disease or disorder associated with a specific CADPKL allelic variant, which method comprises identifying, according to the method of claim 57, the CADPKL allelic variant in a nucleic acid sample from the subject.
- 59. The method of claim 58 wherein the disease or disorder is a neuropsychiatric disorder.
- 60. The method of claim 59 wherein the neuropsychiatric disorder is selected from the group consisting of schizophrenia, schizoaffective disorder, bipolar disorder, unipolar affective disorder and adolescent conduct disorder.
- 61. The method of claim 60 wherein the neuropsychiatric disorder is schizophrenia.

62. A kit for amplifying or determining the molecular structure of at least a portion of a CADPKL nucleic acid, which kit comprises:

a probe or primer capable of hybridizing to the isolated nucleic acid of claim 54; and

instructions for use.